CHINA BIOLOGIC PRODUCTS, INC. 3,000,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENTUnderwriting Agreement • June 10th, 2015 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
The undersigned understands that you propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with China Biologic Products, Inc., a Delaware corporation (the “Company”), and certain selling stockholders to be named therein (the “Selling Stockholders”, providing for the public offering (the “Public Offering”) by the several underwriters to be named therein (the “Underwriters”), for whom you will act as representatives (collectively, the “Representatives”), of an aggregate of 3,000,000 shares (the “Shares”) of the common stock of the Company, par value of $0.0001 each (the “Common Stock”), plus an aggregate of up to an aggregate of 450,000 additional shares, at the option of the Underwriters.
FORM OF REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 5th, 2009 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of June __, 2009, by and between China Biologic Products, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each a “Purchaser” and collectively, the “Purchasers”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • March 23rd, 2012 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement, dated as of March 19, 2012, is made by and between China Biologic Products, Inc., a Delaware corporation (the “Company”), and Yungang Lu, a director of the Company (the “Indemnitee”).
Share Exchange AgreementShare Exchange Agreement • September 5th, 2007 • China Biologic Products, Inc. • New York
This Share Exchange Agreement, dated as of July 18, 2006, is made by and among GRC Holdings, Inc., a Texas corporation (the “Acquiror Company”), Lin Ling LI, Siu Ling CHAN, Michael LI, Katherine LOH and Chao Ming ZHAO (collectively, the “Shareholders”), and Logic Express Limited, a corporation organized under the laws of the British Virgin Islands (the “Company”).
ContractChina Biologic Products, Inc. • September 5th, 2007
NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.
PREFERRED SHARES RIGHTS AGREEMENT Dated as of February 22, 2017 CHINA BIOLOGIC PRODUCTS, INC. and SECURITIES TRANSFER CORPORATION, as Rights AgentPreferred Shares Rights Agreement • February 23rd, 2017 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
This PREFERRED SHARES RIGHTS AGREEMENT (this “Agreement”), dated as of February 22, 2017, is by and between China Biologic Products, Inc., a Delaware corporation (the “Company”), and Securities Transfer Corporation, a Texas corporation, as rights agent (the “Rights Agent”). All capitalized terms that are used in this Agreement shall have the respective meanings given thereto in Section 1.
CHINA BIOLOGIC PRODUCTS, INC.Stock Option Agreement • May 11th, 2012 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • Delaware
Unless otherwise defined herein, the terms in the Stock Option Agreement (the “Option Agreement”) have the same meanings as defined in the China Biologic Products, Inc. 2008 Equity Incentive Plan (the “Plan”).
Employment AgreementEmployment Agreement • March 12th, 2020 • China Biologic Products Holdings, Inc. • Biological products, (no disgnostic substances) • Delaware
This Employment Agreement (this “Agreement”), dated as of August 16, 2019, is entered into between China Biologic Products Holdings, Inc., a company established in the Cayman Islands with its principal office located at 18th Floor, Jialong Int’l Tower, 19 Chaoyang Park Road, Beijing 100125, PRC (“Company”), and Joseph Chow (the “Executive”).
CHINA BIOLOGIC PRODUCTS, INC. INDEPENDENT DIRECTOR AGREEMENTChina Biologic Products • March 23rd, 2012 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT (The “Agreement”) is made as of the 19th day of March 2012 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter referred to as the “Company”), and Yungang Lu (hereinafter referred to as the “Director”).
SHARE PURCHASE AGREEMENT by and between CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. and CITIC CAPITAL MB INVESTMENT LIMITED Dated as of August 24, 2018Share Purchase Agreement • August 27th, 2018 • China Biologic Products Holdings, Inc. • Biological products, (no disgnostic substances) • New York
THIS SHARE PURCHASE AGREEMENT, dated as of August 24, 2018 (this “Agreement”), is by and between China Biologic Products Holdings, Inc., a Cayman Islands exempted company (the “Company”), and CITIC Capital MB Investment Limited, a company organized and existing under the Laws of the Cayman Islands (the “Investor”). The Company and the Investor are referred to in this Agreement collectively as the “Parties” and individually as a “Party.”
INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • August 27th, 2018 • China Biologic Products Holdings, Inc. • Biological products, (no disgnostic substances) • New York
CHINA BIOLOGIC PRODUCTS, INC. 2,775,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENTUnderwriting Agreement • June 6th, 2016 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
The undersigned understands that you propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with China Biologic Products, Inc., a Delaware corporation (the “Company”), and certain selling stockholders to be named therein (the “Selling Stockholders”, providing for the public offering (the “Public Offering”) by the underwriter to be named therein (the “Underwriter”) of certain shares (the “Shares”) of the common stock of the Company, par value of $0.0001 each (the “Common Stock”).
Guarantee Agreement (Applicable to Any Guarantee Provided by Bank)Guarantee Agreement • March 3rd, 2014 • China Biologic Products, Inc. • Biological products, (no disgnostic substances)
This Guarantee Agreement (hereinafter referred to as this “Agreement”) is made and entered into as of February 26, 2014 by and between:
REPURCHASE AGREEMENTRepurchase Agreement • February 7th, 2014 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
This REPURCHASE AGREEMENT (this “Agreement”) dated as of January 27, 2014 is made by and among China Biologic Products, Inc., a Delaware corporation (the “Company”), Ms. Siu Ling Chan, a Hong Kong resident (ID No. P725946(1), “Seller”) and Mr. Lam Tung, a Hong Kong resident (ID No. P665194(5), “Seller Affiliate”). The Company, Seller and Seller Affiliate are hereinafter referred to as the “Parties” and each a “Party”.
CHINA BIOLOGIC PRODUCTS, INC. DIRECTOR AGREEMENTChina Biologic Products • March 4th, 2015 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT (The “Agreement”) is made on March 4, 2015 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter referred to as the “Company”), and Mr. Min Fang (hereinafter referred to as the “Director”).
Raw Plasma Supply AgreementPlasma Supply Agreement • September 5th, 2007 • China Biologic Products, Inc.
According to item 13 of the Regulation “Controlling of Blood Products”, a plasma collection station may only supply raw plasma to one blood products manufacturer under quality credential agreement, raw plasma supply to other manufacturers is forbidden. According to MOH standards, the plasma collection station and blood products manufacturer must sign an agreement for the supply of raw plasma.
Employment AgreementEmployment Agreement • May 13th, 2008 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • Delaware
This Employment Agreement (“Agreement”), dated as of June, 1, 2008, is entered into between China Biologic Products, Inc., a company established in the United States with its principal office located at No. 14., East Hushan Road, Taian City, Shandong, PRC (“Company”), and Yu-Yun Tristan Kuo (the “Executive”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 17th, 2013 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 14, 2013, by and between China Biologic Products, Inc., a Delaware corporation (the “Company”) and WP X Biologics LLC (the “Purchaser”).
SHARE PURCHASE AGREEMENTShare Purchase Agreement • May 1st, 2013 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
This SHARE PURCHASE AGREEMENT (this “Agreement”) dated as of April 29, 2013 is made by and among WP X Biologics LLC, a Delaware limited liability company (“Purchaser”), Ms. Lin Ling Li, a Hong Kong resident (Hong Kong ID No. R330968(0), “Seller”) and Mr. Ze Qin Lin, a Hong Kong resident (Hong Kong ID No. P774319(3)) and husband of Seller (“Seller Affiliate”). Purchaser, Seller and Seller Affiliate are hereinafter referred to as the “Parties” and each a “Party”.
AGREEMENT AND PLAN OF MERGER Among CHINA BIOLOGIC PRODUCTS HOLDINGS, INC., CBPO HOLDINGS LIMITED and CBPO GROUP LIMITED Dated as of November 19, 2020Agreement and Plan of Merger • November 19th, 2020 • China Biologic Products Holdings, Inc. • Biological products, (no disgnostic substances) • New York
This AGREEMENT AND PLAN OF MERGER, dated as of November 19, 2020 (this “Agreement”), is entered into by and among China Biologic Products Holdings, Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “Company”), CBPO Holdings Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands (“Parent”), and CBPO Group Limited, an exempted company with limited liability incorporated under the Laws of the Cayman Islands and a wholly owned subsidiary of Parent (“Merger Sub” and, together with the Company and Parent, the “Parties” and each, a “Party”).
Asset Purchase Agreement (Translated Version)Asset Purchase Agreement • December 3rd, 2007 • China Biologic Products, Inc. • Biological products, (no disgnostic substances)
According to Ministry of Health and the 9 other ministries and commissions jointly issued notice (Wei Yi Fa (2006) No. 118) regarding <Measure on the Transformation of Plasma Collection Station (Lu Wei Yi Zi (206) No.68)>, and the approval document issued by Guangxi Autonomous Region Health Department regarding <Forwarding Ministry of Health’s Notification Concerning Reporting the progress on the Measures on reforming plasma collection stations (Gui Wei Yi (2007) No.2>, both parties has mutually agreed to enter into a plasma station assets transfer contract for the benefit of the Provincial development on plasma products and health industry, for the stability of personnel and for the long term development of plasma collection station.
Registered Equity Purchase Agreement (Summary Translation)Registered Equity Purchase Agreement • August 25th, 2014 • China Biologic Products, Inc. • Biological products, (no disgnostic substances)
This Registered Equity Purchase Agreement (this “Agreement”) is entered into on August 21, 2014 by and between Guiyang Dalin Biotechnology Co., Ltd. (the “Purchaser”) and Guizhou Eakan Pharmaceutical Co., Ltd. (the “Seller”).
AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • April 28th, 2017 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • Delaware
CHINA BIOLOGIC PRODUCTS, INC. INDEPENDENT DIRECTOR AGREEMENTChina Biologic Products • November 6th, 2014 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT (The “Agreement”) is made as of the 3th day of November 2014 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter referred to as the “Company”), and Mr. Joseph Chow (hereinafter referred to as the “Director”).
CREDIT AGREEMENT Dated as of February 25, 2014 between CHINA BIOLOGIC PRODUCTS, INC. as Borrower, and CHINA MERCHANTS BANK CO., LTD., NEW YORK BRANCH as LenderCredit Agreement • March 3rd, 2014 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
This CREDIT AGREEMENT dated as of February 25, 2014 (as the same may be amended, restated or otherwise modified from time to time, the “Credit Agreement”) between CHINA BIOLOGIC PRODUCTS, INC. (the “Borrower”), and CHINA MERCHANTS BANK CO., LTD., NEW YORK BRANCH (the “Lender”).
Joint Venture and Cooperation Agreement between ShareholdersChina Biologic Products, Inc. • October 16th, 2008 • Biological products, (no disgnostic substances)
Whereas, Party A entered into a Joint Venture and Cooperation Agreement between Shareholders with FAN Qingchun ("Transferor") on November 8, 2005 for purpose of joint acquisition of 68% equity interest held by Jiao Da Rui Shen in Huitian Blood Products Co., Ltd. ("Huitian"). After the acquisition, Party A held 65% of the equity interests in Huitian, while the Transferor held 35% of the equity interests in Huitian. After registration of the equity transfer with the administration for industry and commerce, both Parties have been jointly operating Huitian till now. In July 2008, the Transferor proposed to transfer 35% of the equity interests it held in Huitian due to its own reasons and recommended Party B as the Transferee.
Supplemental Equity Transfer Agreement English TranslationSupplemental Equity Transfer Agreement • April 23rd, 2009 • China Biologic Products, Inc. • Biological products, (no disgnostic substances)
This Supplemental Equity Transfer Agreement is entered into as of April 18, 2009 in Tai'an city by and between the following parties:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 5th, 2007 • China Biologic Products, Inc. • New York
This Registration Rights Agreement (this "Agreement") is made and entered into as of July 18, 2006, by and among GRC Holdings, Inc., a Texas corporation (the "Company"), and the investors signatory hereto (each a "Investor" and collectively, the "Investors").
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 5th, 2007 • China Biologic Products, Inc. • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 18, 2006, among GRC Holdings, Inc., a Texas corporation (“GRC”) and its wholly-owned subsidiary, Logic Express Limited (“Logic Express”), and its 82.76% owned subsidiary Shandong Missile Biologic Products Co., Ltd. (“Shandong Missile” or the “Company”), the selling stockholders identified on the signature pages hereto (each, a “Selling Stockholder,” and collectively, the “Selling Stockholders”) and the investors identified on the signature pages hereto (each, an “Investor” and collectively, the “Investors”).
AMENDMENT NO. 1 TO SHARE ESCROW AGREEMENTShare Escrow Agreement • September 5th, 2007 • China Biologic Products, Inc.
This AMENDMENT NO. 1 to the SHARE ESCROW AGREEMENT is entered into as of February 16, 2007 (this “Amendment”) by and among China Biologic Products, Inc., a Delaware corporation (formerly, GRC Holdings, Inc.) (the “Company”), Lane Capital Markets, LLC, as representative of the Investors (the “Investor Representative”), Ms. Lin Ling Li and Ms. Siu Ling Chan (together, the “Stockholders”), and Security Transfer Corporation, as escrow agent (the “Escrow Agent”). Each of the Company, the Investor Representative, the Stockholders and the Escrow Agent are referred to herein as a “Party” and collectively, as the “Parties”. Capitalized terms used, but not otherwise defined, herein have the meanings ascribed to such terms in the Original Agreement (as defined below).
Employment AgreementEmployment Agreement • March 6th, 2019 • China Biologic Products Holdings, Inc. • Biological products, (no disgnostic substances)
This Employment Agreement (this “Agreement”), dated as of December 3, 2018, is entered into between China Biologic Products Holdings, Inc., a company established in the Cayman Islands with its principal office located at 18th Floor, Jialong Int’l Tower, 19 Chaoyang Park Road, Beijing 100125, PRC (“Company”), and Huaming He (the “Executive”).
English Translation) Employment AgreementTranslation) Employment Agreement • December 3rd, 2007 • China Biologic Products, Inc. • Biological products, (no disgnostic substances)
The contract is entered and signed on March 8, 2007 between China Biologic Products, Inc, a company established in the U.S. with its principal office located at No. 14., Eash Hushan Road, Taian City, Shandong, PRC ("Company") and Stanley Wong, a Hong Kong permanent resident ("Employee").
Trademark License Agreement (English Translation)Trademark License Agreement • December 3rd, 2007 • China Biologic Products, Inc. • Biological products, (no disgnostic substances)
Under section 40 of Trademark Law of People’s Republic of China and section 43 of Implementing Rules of the Trademark Law of the People’s Republic of China, this Trademark License Agreement is made by and between Party A and Party B as follows.
Asset Station Purchase Agreement (Translated Version)Asset Station Purchase Agreement • December 3rd, 2007 • China Biologic Products, Inc. • Biological products, (no disgnostic substances)
According to Ministry of Health and the 9 other ministries and commissions jointly issued notice (Wei Yi Fa (2006) No. 118) regarding <Measure on the Transformation of Plasma Collection Station (Lu Wei Yi Zi (206) No.68)>, and the approval document issued by Shandong Health Department regarding <Agreement on Shandong Missile Biological Co Ltd to acquire plasma collection station in Shandong Province>, both parties has mutually agreed to enter into a plasma station assets transfer contract for the benefit of the Provincial development on plasma products and health industry, for the stability of personnel and for the long term development of plasma collection station.
CHINA BIOLOGIC PRODUCTS, INC. AMENDED AND RESTATED DIRECTOR AGREEMENTDirector Agreement • February 25th, 2016 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT (this “Agreement”) is made as of the 22rd day of February, 2016 and is by and between China Biologic Products, Inc., a Delaware corporation (the “Company”), and Mr. David Li (the “Director”).
